PuraCath Medical Presents Data on the Company’s Proprietary Infection Reduction Technology during the National Science Foundation’s SBIR Phase II Grantee Conference

Atlanta, Georgia (June 2, 2015) – PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients on dialysis therapy, announced today that the company was a featured presenter during the National Science Foundation’s (NSF) Small Business Innovation Research (SBIR) 2015 Phase II Grantee Conference held in Atlanta, Georgia. PuraCath presented data from research funded by a NSF SBIR Phase II grant for the project “Novel Peritoneal Dialysis Catheter to Reduce Infections” which demonstrated the ability to reduce bacterial growth in a simulated peritoneal dialysis delivery system when combining ultraviolet (UV) light with a UV transmissible connection system.

“PuraCath is honored to be selected to present data summarizing the results of studies with our technology which was funded by a generous Phase II and IIB grant associated with the NSF’s SBIR Grant program,” said Julia Rasooly, PuraCath Medical’s CEO. “We are proud to have been a recipient and the primary investigator for Phase I, IB, II and IIB NSF SBIR Grants with a total cumulative grant amount of $1.3 million. This non-­‐ dilutive funding, which has supported research and development initiatives for our proprietary technology to date, is a testimony to the medical need to reduce infectious complications in patients on PD therapy.”

“The support PuraCath Medical has received via NSF SBIR grants has permitted the Company to further demonstrate the clinical potential its UV light-­‐based technology has to reduce infectious complications in patients on peritoneal dialysis, allowing further growth in the use of this patient-­‐friendly and higher quality of life, lifesaving therapy,” stated nephrologist Glenn Chertow, M.D. “The ability of PuraCath’s management team to successfully obtain sequential SBIR Grants and the subsequent development of the company’s technology is a testimony to their ability to deliver results and the validates the company’s approach to improve patient outcomes in patients on dialysis therapy.

WHAT IS PERITONEAL DIALYSIS?
Peritoneal dialysis is a home-­‐based dialysis therapy that offers patients a more flexible and physiologically smoother dialysis option. Unlike hemodialysis, peritoneal dialysis uses a patient’s peritoneal membrane to remove toxins and excess fluid from a patient. Peritoneal dialysis therapy permits patients to have a more regular diet and more flexible treatment times, improving their quality of life. Currently there are nearly
40,000 peritoneal patients on dialysis therapy in the U.S. with the number of patients on this therapy increasing over the past several years. The most common complications from peritoneal dialysis include infection around the catheter site or infection of the lining of the abdominal wall (peritonitis).

ABOUT PURACATH MEDICAL
PuraCath Medical is a company based in San Francisco, CA and is dedicated to improving the quality of life of patients on dialysis therapy by reducing infections related to peritoneal dialysis (PD) and saving time through improved, simplified connection of PD catheters. The Company utilizes technology that was spun out of Stanford University and is developing a novel easy-­‐to-­‐use technology designed to reduce infections and improve outcomes for patients on PD therapy. For more information on PuraCath Medical, please visit www.puracath.com.

PuraCath Medical Presents Study at National Kidney Foundation 2015 Spring Clinical Meetings

Company presents new data on the effectiveness of UV light to purify peritoneal dialysis catheter connections across a wider range of microorganisms that contribute to infections in PD patients

Dallas, Texas (March 27, 2015) – PuraCath Medical, an emerging company in the development of technologies to reduce infections in patients with intravascular and peritoneal catheters, announced today that it presented new scientific data on its proprietary ultraviolet light-based technology during the National Kidney Foundation’s (NKF) 2015 Spring Clinical Meetings. The study presented reported on the ability to reduce bacterial growth in a simulated peritoneal dialysis delivery system when combining ultraviolet (UV) light with a UV transmissible connection system. This data confirms the effectiveness of combining UV light with a UV transmissible connection system to reduce bacterial growth across a wider range of bacteria and a fungi (Candida albicans) which are known to contribute to infections and peritonitis in peritoneal dialysis patients. The current study builds on earlier research the company presented at the American Society of Nephrology meeting in 2014.

“PuraCath Medical’s technology is a revolutionary approach to reducing the risk of infections that could lead to a change in the way peritoneal dialysis is performed,” stated Alberto Sabucedo, M.D., Ph.D., from the Department of Nephrology and Hypertension at the University of Miami. “This is a promising technology that will enable a better quality of life for patients on peritoneal dialysis, and I look forward to utilizing in my practice when it is available for clinical use.”

“While there is increasing interest in the use of peritoneal dialysis therapy to manage patients with end-stage renal disease, patients still currently remain at risk of developing infections and peritonitis from low compliance with rigorous disinfection protocols, impacting their ability to remain on this therapy for the long term,” said Julia Rasooly, PuraCath Medical’s CEO. “The study we presented at the NKF meeting confirms that our approach to reduce bacterial growth through the use of a novel UV light-based PD purification system is effective across a wider range of microorganisms than we initially tested. Based on the results of this study and the rapid progress we have made with our product development efforts to date, we look to initiate the first clinical studies of our technology in PD patients in the near future. PuraCath believes in the value and the lifestyle convenience peritoneal dialysis therapy offers to patients and we are developing a PD disinfection system that enhances PD patient’s quality of life and also provides an easy-to-use, patient friendly option to reducing bacterial and fungal contamination during PD exchanges. We feel confident that this will allow a broader range of patients to benefit from the quality of life of treatment on PD.”

WHAT IS PERITONEAL DIALYSIS?

Peritoneal dialysis is a home-based dialysis therapy that offers patients a more flexible and physiologically smoother dialysis option. Unlike hemodialysis, peritoneal dialysis uses a patient’s peritoneal membrane to remove toxins and excess fluid from a patient. Peritoneal dialysis therapy permits patients to have a more regular diet and more flexible treatment times, improving their quality of life. Currently there are over 45,000 peritoneal dialysis patients in the U.S. with the number of patients on this therapy increasing over the past several years. The most common complications from peritoneal dialysis include infection around the catheter site or infection of the lining of the abdominal wall (peritonitis).

ABOUT PURACATH MEDICAL

PuraCath Medical is a company based in San Francisco, CA and is dedicated to improving the quality of life for the dialysis patient by reducing infections related to peritoneal dialysis (PD) and saving time through improved, simplified connection of PD catheters. The Company utilizes technology that was spun out of Stanford University and is developing a novel, easy-to-use technology designed to reduce the risk of infections in patients with intravascular and peritoneal catheters in order to decrease infection-related hospitalizations and their associated costs.

For more information on PuraCath Medical, please visit www.puracath.com.

CONTACT
Julia Rasooly, M.S.
Founder and Chief Executive Officer
PuraCath Medical Inc.
+1.650.559.0388

PuraCath Medical Presents Data at 2014 Annual Meeting of the American Society of Nephrology

Company presents study on the effectiveness of UV light to purify peritoneal dialysis catheter connections

PuraCath Medical, an emerging company in the development of technologies to reduce infections in dialysis patients, announced today that it presented scientific data during Kidney Week 2014 demonstrating the ability to reduce bacterial growth in a simulated peritoneal dialysis delivery system when combining ultraviolet (UV) light with a UV transmissible connection system. The study represents early results with an initial version of the technology PuraCath Medical is developing which will be designed to reduce connectology-related bacterial contamination for PD patients.

“Infectious complications remain a major risk for patients receiving PD and represent a leading cause of technique failure and transition to hemodialysis,” stated study co-author and nephrologist Glenn Chertow, M.D. “Approaches that can reduce bacterial contamination during peritoneal exchanges should reduce the risk of peritonitis and allow patients to remain on home-based therapy. In order to allow patients to choose PD and to remain on PD long-term, we need to reduce peritonitis risk. I believe the approach PuraCath Medical is taking will help us get there.”

“We are encouraged by the study results we presented during the ASN meeting which support our planned development of a novel UV light-based PD purification system,” said Julia Rasooly, PuraCath Medical’s CEO. “Since PuraCath Medical recognizes the value and the lifestyle convenience peritoneal dialysis therapy offers to patients, we are developing a PD disinfection system that enhances their quality of life and provides an easy-to-use, patient friendly option to reducing bacterial and fungal contamination during PD exchanges.”

WHAT IS PERITONEAL DIALYSIS?
Peritoneal dialysis is a home-based dialysis therapy that offers patients a more flexible and physiologically smoother dialysis option. Unlike hemodialysis, peritoneal dialysis uses a patient’s peritoneal membrane to remove toxins and excess fluid from a patient. Peritoneal dialysis therapy permits patients to have a more regular diet and more flexible treatment times, improving their quality of life. Currently there are nearly 40,000 peritoneal dialysis patients in the U.S. with the number of patients on this therapy increasing over the past several years. The most common complications from peritoneal dialysis include infection around the catheter site or infection of the lining of the abdominal wall (peritonitis).

ABOUT PURACATH MEDICAL
PuraCath Medical is a company based in Mountain View, CA and is dedicated to improving the quality of life for the dialysis patient by reducing infections related to peritoneal dialysis (PD) and saving time through improved, simplified connection of PD catheters. The Company utilizes technology that was spun out of Stanford University and is developing a novel easy-to-use technology designed to reduce infections and improve outcomes for patients on PD therapy. For more information on PuraCath Medical, please visit http://www.puracath.com.

CONTACT
Julia Rasooly, M.S.
President and Chief Executive Officer
+1.650.559.0388

KHI stakeholders conference 2014 – June 11-12, 2014

ima_thumb

To advance scientific understanding of the kidney health and patient safety implications of new and existing medical products and to foster development of therapies for diseases that affect the kidney by creating a collaborative environment in which FDA and the greater nephrology community can interact to optimize evaluation of drugs, devices, biologics, and food products.